Micro architecture, the key to bone quality

被引:165
作者
Brandi, Maria Luisa [1 ]
机构
[1] Univ Florence, Dept Internal Med, I-50139 Florence, Italy
关键词
Bone modelling; Bone remodelling; Osteoporosis; Microarchitecture; HUMAN TRABECULAR BONE; MINERAL DENSITY; NONVERTEBRAL FRACTURE; REGULATORY MECHANISMS; OVARIECTOMIZED RATS; PARATHYROID-HORMONE; OSTEOPOROSIS; NANOINDENTATION; OSTEOCLAST; STRENGTH;
D O I
10.1093/rheumatology/kep273
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Bone has the ability to adapt its shape and size in response to mechanical loads via a process known as modelling in which bones are shaped or reshaped by the independent action of osteoblasts and osteoclasts. Remodelling is a process that maintains mechanical integrity of the skeleton, allowing it to selectively repair and replace damaged bone. During adulthood, bone remodelling is the dominant process, after the age of 40 years, the age-related decline in bone mass increases the risk of fracture, especially in women Osteoporosis is defined as a reduction in bone mass and an impairment of bone architecture resulting in thinning and increased cortical porosity, bone fragility and fracture risk As new products and methods have been developed, focusing on bone fragility, effective and sensitive non-invasive means able to detect early changes in bone fragility process have also been developed Due to limitations in assessing fracture risk and response to therapy, the evaluation of bone mineral contents by bone densitometry is progressively replaced by new non-invasive and/or non-destructive techniques able to estimate bone strength, providing structural information about the pathophysiology of bone fragility by quantitative assessments of macro- and microstructural bone features DXA and volumetric QCT quantify bone macrostructure, whereas high-resolution CT, microCT, high-resolution MR and microMR assess bone microstructure Knowledge of bone microarchitecture is a clue for understanding osteoporosis pathophysiology and improving its diagnosis and treatment; the response of microarchitecture parameters to treatment should allow assessment of the real efficacy of the osteoporosis therapy
引用
收藏
页码:IV3 / IV8
页数:6
相关论文
共 42 条
[1]
Bone density and shape as determinants of bone strength in IGF-I and/or pamidronate-treated ovariectomized rats [J].
Ammann, P ;
Rizzoli, R ;
Meyer, JM ;
Bonjour, JP .
OSTEOPOROSIS INTERNATIONAL, 1996, 6 (03) :219-227
[2]
The new selective estrogen receptor modulator MDL 103,323 increases bone mineral density and bone strength in adult ovariectomized rats [J].
Ammann, P ;
Bourrin, S ;
Bonjour, JP ;
Brunner, F ;
Meyer, JM ;
Rizzoli, R .
OSTEOPOROSIS INTERNATIONAL, 1999, 10 (05) :369-376
[3]
Matrix vesicles and calcification. [J].
H. Clarke Anderson .
Current Rheumatology Reports, 2003, 5 (3) :222-226
[4]
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis [J].
Black, DM ;
Greenspan, SL ;
Ensrud, KE ;
Palermo, L ;
McGowan, JA ;
Lang, TF ;
Garnero, P ;
Bouxsein, ML ;
Bilezikian, JP ;
Rosen, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (13) :1207-1215
[5]
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis [J].
Black, DM ;
Bilezikian, JP ;
Ensrud, KE ;
Greenspan, SL ;
Palermo, L ;
Hue, T ;
Lang, TF ;
McGowan, JA ;
Rosen, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (06) :555-565
[6]
Blair HC, 2004, HISTOL HISTOPATHOL, V19, P189, DOI 10.14670/HH-19.189
[7]
Technology insight: noninvasive assessment of bone strength in osteoporosis [J].
Bouxsein, Mary L. .
NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2008, 4 (06) :310-318
[8]
Determinants of skeletal fragility [J].
Bouxsein, ML .
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2005, 19 (06) :897-911
[9]
Osteoclast differentiation and activation [J].
Boyle, WJ ;
Simonet, WS ;
Lacey, DL .
NATURE, 2003, 423 (6937) :337-342
[10]
Chappard D., 2008, Morphologie, V92, P162, DOI 10.1016/j.morpho.2008.10.003